View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 17, 2020updated 12 Jul 2022 11:55am

New Zealand researchers work on three Covid-19 trials

Researchers at Medical Research Institute of New Zealand have announced REMAP-CAP, MRINZ and ASCOT clinical trials to study potential treatments for Covid-19.

Researchers at Medical Research Institute of New Zealand have announced REMAP-CAP, MRINZ and ASCOT clinical trials to study potential treatments for Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Led by the institute, REMAP-CAP is the largest trial and has been already started at more than 65 Intensive Care Units (ICUs) in 13 countries globally.

Researchers in Australia, New Zealand, UK, the Netherlands, Canada and the US are primarily responsible for the trial, which is designed for adaption based on the pandemic status.

It is designed to evaluate various Covid-19 drug candidates, including lopinavir/ritonavir, hydroxychloroquine, azithromycin and steroids, among other immune modulating treatments.

REMAP-CAP trial co-leader Dr Colin McArthur said: “It allows us to evaluate several treatments at the same time, in the same patient, combining the results from around the world, then use this to influence care for future patients, to ensure they too are more likely to receive the best treatment regime available.

“We can quickly drop treatments if they are shown to be less effective than others or worse than standard care, and add others to the study over time if need be.”

Meanwhile, the MRINZ trial will assess hydroxychloroquine as a prophylaxis therapy for frontline healthcare workers who are at high risk for Covid-19 due to exposure to patients.

The trial will be conducted if the number of Covid-19 cases in New Zealand increases over the next few months and will involve frontline healthcare workers.

MRINZ is also involved with ASCOT, a collaborative trial led in New Zealand by Middlemore Hospital.

This study will compare lopinavir/ritonavir and hydroxychloroquine either alone or in combination, to full standard supportive care, in hospitalised patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena